{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:24:11Z","timestamp":1788830651904,"version":"build-2803163510"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>The anti-programmed cell death (PD-1) checkpoint inhibitor pembrolizumab is approved for the treatment of cervical carcinoma with a programmed cell death-ligand 1 (PD-L1) Combined Positive Score (CPS) of \u22651. We assessed interobserver agreement in cervical carcinoma PD-L1 CPS to identify whether it may affect patient selection for immunotherapeutic candidacy. Twenty-nine cervical carcinomas were stained for PD-L1 (Dako 22C3), and slides were interpreted by 5 subspecialty-trained gynecologic pathologists with experience reading PD-L1 immunohistochemistry. Expression was scored using CPS and read out as positive (\u22651) or negative (&lt;1); in positive cases, a final score was assigned (1 to 100). There was consensus agreement across all 5 pathologists for 90% (26\/29) (Fleiss Kappa value for interobserver agreement: 0.799). The 3 cases with disagreement were composed of 2 squamous cell carcinomas and 1 small cell carcinoma. Of the 26 with unanimous agreement, 88% (23\/26) were positive and 12% (3\/26) were negative. All (16\/16) pure squamous cell carcinomas with full consensus were interpreted as positive, whereas tumors with glandular components were commonly consensus negative (33%, 3\/9); this difference was significant (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.037). Disagreements were attributable to low CPS versus negative reads (2 cases) and difficulty discerning glandular involvement from pushing invasion (1 case). In summary, experienced gynecologic pathologists showed substantial interobserver agreement in the interpretation of PD-L1 CPS at the Food and Drug Administration\u2013approved treatment threshold, with the majority of tumors being classified as positive. Pure squamous histology was strongly associated with a consensus-positive read, whereas a subset of tumors with glandular differentiation was negative by all readers. Disagreements occurred in tumors with low versus negative CPS values and in the setting of limited invasion.<\/jats:p>","DOI":"10.1097\/pas.0000000000002058","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T08:00:07Z","timestamp":1685952007000},"page":"889-896","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Interobserver Agreement on the Interpretation of Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Among Gynecologic Pathologists"],"prefix":"10.1097","volume":"47","author":[{"given":"Anne M.","family":"Mills","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Virginia Health System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Banet","sequence":"additional","affiliation":[{"name":"Department of Pathology Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn C.","family":"Watkins","sequence":"additional","affiliation":[{"name":"Department of Pathology Massachusetts General Hospital, Harvard Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debamita","family":"Kundu","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Virginia Health System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Miami Health System"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Eng J Med"},{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Eng J Med"},{"key":"R3-20250608","first-page":"5955","article-title":"Immune checkpoint inhibitors in gynecological cancers: update of literature and perspectives of clinical research","volume":"37","author":"Gadducci","year":"2017","journal-title":"Anticancer Res"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"Am J Clin Oncolgy"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"e14589","DOI":"10.1200\/JCO.2017.35.15_suppl.e14589","article-title":"Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx","volume":"35","author":"Kulangara","year":"2017","journal-title":"J Clin Oncol"},{"key":"R10-20250608","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","author":"Kulangara","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40291-022-00605-2","article-title":"Indirect clinical validation of a programmed death-ligand 1 laboratory-developed test for gastric\/gastroesophageal junction adenocarcinoma with 22C3 antibody concentrate","volume":"26","author":"Kim","year":"2022","journal-title":"Mol Diagn Ther"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.breast.2021.11.003","article-title":"Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer","volume":"60","author":"Noske","year":"2021","journal-title":"Breast"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"442","DOI":"10.5858\/arpa.2021-0464-OA","article-title":"Programmed death ligand-1 combined positive score concordance and interrater reliability in primary tumors and synchronous lymph node metastases in resected cases of p16+ oropharyngeal squamous cell carcinoma","volume":"147","author":"Kaur","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/his.14775","article-title":"High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications","volume":"81","author":"Nuti","year":"2022","journal-title":"Histopathology"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamaoncol.2018.5441","article-title":"Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study","volume":"5","author":"Shah","year":"2019","journal-title":"JAMA Oncol"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ygyno.2020.08.026","article-title":"PD-1 blockade in recurrent or metastatic cervical cancer: data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer","volume":"159","author":"Rischin","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"100128","DOI":"10.1016\/j.modpat.2023.100128","article-title":"Multi-institutional study of pathologist reading of the PD-L1 combined positive score (CPS) immunohistochemistry assay in gastric or gastroesophageal junction cancer","volume":"36","author":"Fernandez","year":"2023","journal-title":"Mod Pathol"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00428-019-02653-2","article-title":"PD-L1 expression in gastric cancer determined by digital image analyses: pitfalls and correlation with pathologist interpretation","volume":"476","author":"Kim","year":"2020","journal-title":"Virchows Arch"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/his.13723","article-title":"PD-L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy","volume":"74","author":"Chinn","year":"2019","journal-title":"Histopathology"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/PAS.0000000000001506","article-title":"Loss of MHC class i expression in HPV-associated cervical and vulvar neoplasia: a potential mechanism of resistance to checkpoint inhibition","volume":"44","author":"Dibbern","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.21037\/tcr-20-101","article-title":"High concordance of programmed death-ligand 1 expression with immunohistochemistry detection between antibody clones 22C3 and E1L3N in non-small cell lung cancer biopsy samples","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl Cancer Res"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1007\/s00404-022-06529-w","article-title":"Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients","volume":"306","author":"Schmidt","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s10120-022-01301-0","article-title":"Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy","volume":"25","author":"Yeong","year":"2022","journal-title":"Gastric Cancer"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/aogs.14404","article-title":"PD-L1 in gestational trophoblastic disease: an antibody evaluation","volume":"101","author":"Hoeijmakers","year":"2022","journal-title":"Acta Obstet Gynecol Scand"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:00:11Z","timestamp":1749416411000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002058","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,5]]}}}